OR WAIT null SECS
September 27, 2019
Nanoform and AstraZeneca have agreed to start a technology evaluation of Nanoform’s CESS Technology across a range of AstraZeneca’s pharmaceutical products.
AstraZeneca and GlaxoSmithKline have been ranked in the top 20 companies for outstanding efforts in sustainability performance in the FTSE 100 Index climate change business leaderboard, published by EcoAct.
ABPI has issued a response to the recently published report from the National Audit Office (NAO) on the impact Brexit may have on medicines supply.
GE Healthcare announced that it is partnering with several companies and academic institutions with the aim of developing a portfolio of targeted oncology positron emission tomography (PET) tracers.
BioIVT has announced that it has joined the Medicines Discovery Catapult’s Discovery Services Platform, which is aimed at supporting drug discovery within the United Kingdom.
BIA will be hosting a series of events and webinars to support small-and-medium sized enterprises in life sciences in the preparations for a possible ‘no-deal’ Brexit.
September 24, 2019
The project focused on accelerating the discovery and development of monoclonal antibodies and aimed to tackle the limitations in the biologics supply chain.
September 23, 2019
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of AstraZeneca’s Qtrilmet (metformin hydrochloride, saxagliptin, and dapagliflozin) modified-release tablets for treating type-2 diabetes.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion recommending marketing authorization for Bavencio (avelumab) in combination with axitinib for treating kidney cancer.
September 20, 2019
A request has been made to the CHMP by the executive director of EMA to provide guidance on how to avoid the presence of nitrosamine impurities in human medicines.